Skip to main content
ACS AuthorChoice logoLink to ACS AuthorChoice
. 2023 Sep 26;23(19):8881–8890. doi: 10.1021/acs.nanolett.3c01983

Cytoplasm Hydrogelation-Mediated Cardiomyocyte Sponge Alleviated Coxsackievirus B3 Infection

Jingzhe Wang †,‡, Tonggong Liu †, Siyao Gu §, Hui-hui Yang †, Weidong Xie §,*, Cheng Gao †,*, Dayong Gu †,*
PMCID: PMC10573321  PMID: 37751402

Abstract

graphic file with name nl3c01983_0006.jpg

Viral myocarditis (VMC), commonly caused by coxsackievirus B3 (CVB3) infection, lacks specific treatments and leads to serious heart conditions. Current treatments, such as IFNα and ribavirin, show limited effectiveness. Herein, rather than inhibiting virus replication, this study introduces a novel cardiomyocyte sponge, intracellular gelated cardiomyocytes (GCs), to trap and neutralize CVB3 via a receptor–ligand interaction, such as CAR and CD55. By maintaining cellular morphology, GCs serve as sponges for CVB3, inhibiting infection. In vitro results revealed that GCs could inhibit CVB3 infection on HeLa cells. In vivo, GCs exhibited a strong immune escape ability and effectively inhibited CVB3-induced viral myocarditis with a high safety profile. The most significant implication of this study is to develop a universal antivirus infection strategy via intracellular gelation of the host cell, which can be employed not only for treating defined pathogenic viruses but also for a rapid response to infection outbreaks caused by mutable and unknown viruses.

Keywords: antiretroviral strategy, coxsackievirus B3, hydrogel, virus neutralization, cellular sponge


Group B coxsackievirus (CVB), part of a small RNA family, leads to life-threatening inflammatory diseases, especially in infants.1 CVB comprises six different serotypes (CVB1–CVB6) and is a significant human pathogen responsible for febrile illnesses, as well as diseases affecting the heart, pancreas, and central nervous system.2−4 Among these serotypes, CVB3 is one of the most common viruses that cause viral myocarditis (VMC), a leading cause of dilated cardiomyopathy and sudden cardiac death.5 Current treatments for VMC rely on broad-spectrum antivirals and supportive care.6 Broad-spectrum antiviral drugs work by targeting the virus envelope, capsid protein, and polymerase to inhibit viral replication. However, their nonspecific property and off-target effect may lead to significant side effects.7−9 Due to the capacity of antibodies to specifically recognize and bind to viral surface antigens, the development of antiviral antibodies has become a primary focus in current scientific research.10−12 Although antibody therapy possesses excellent specificity, it also has significant limitations. The rapid mutation of viruses may hamper the efficacy of a single antibody when confronting virus mutation or coinfection with multiple viruses.13,14 Furthermore, the production of antibodies is typically time-consuming and costly, with the speed of production often unable to keep up with the pace of viral mutation.15,16 Supportive care leans on the patient’s immunity, which can burden those with weakened immunity.17 Therefore, the search for an effective treatment for VMC remains a significant challenge.

CVB3 infects host cells through receptor-mediated endocytosis,18 and coxsackievirus and adenovirus receptors (CAR) are highly expressed on the surface of susceptible target cells for CVB3 infection. CAR acts as a universal stripping receptor that binds to surface depressions (canyons) on the capsid apex of the CVB3 dodecahedron, releasing liposomes that are hidden within the hydrophobic pocket formed by the capsid protein VP1.19,20 The liposome, known as “pocket factor”, is derived from host cells and can promote the destabilization and disintegration of viral particles.21 With the development of biomimetic nanomedicine, it has been widely reported that the host cell membrane was isolated to coat the nanomaterial and inherit the membrane function of the source cell. Due to the specific recognition between the virus and host cell, these membrane-coated nanomedicines were explored to bind and neutralize the virus for antivirus therapy.22−25 However, the membrane separation from the host cell and reassembly process on templated nanomaterial involved protein loss and spatial disorder, which diminished the adsorption efficiency of membrane-coated nanomedicine to viruses. Additionally, the heterogeneity of nanomaterials could trigger an immune response and cause various side effects. Therefore, a new generation of biomimetic cells with intact membrane structure holds the potential to efficiently neutralize the virus.

To quickly respond to virus infection outbreaks, this study developed a novel cellular sponge for virus sequestration and clearance based on specific recognition of host cells by viruses, without defining any specific receptor in the host cell membrane (Figure 1). Regarding the selective infection of CVB3, the hydrogel was prepared in cardiomyocyte cytoplasm to construct GCs. Hydrogel served as an ideal cytoskeletal structure to preserve the intact morphology and membrane protein structure of host cells while eliminating the proliferation and pathogenicity ability. Subcutaneously, GCs adsorbed viruses through specific membrane receptor-mediated recognition, such as CAR and CD55,3,26 as well as other unidentified receptors. Instead of endocytosis through receptors, viruses attached on the GC surface lost the infection ability to normal host cells, and the in vitro attenuation effect of GCs was evaluated in CVB3-infected cardiomyocyte. Due to the maintenance of cell morphology, GCs camouflaged themselves from the mononuclear phagocytic system and exhibited a good systemic safety profile. In a mouse model of viral myocarditis, the therapeutic efficacy of GCs was verified against CVB3-induced VMC. The development of GCs based on cellular sponges, rather than directly inhibiting virus replication, offers a rapid and effective antiviral therapy strategy, which only needed to select appropriate host cells according to the corresponding virus type. Moreover, it is particularly promising in response to large-scale infections caused by rapidly spreading viruses like COVID-19, even when the specific virus receptor is unknown.

Figure 1.

Figure 1

Schematic illustration of GCs inhibiting CVB3 infectivity. GCs were prepared through intracellular hydrogelation to preserve the intact cellular morphology and membrane structure. Benefiting from surface crucial antigens, such as CAR and CD55 receptors, GCs were disguised as cardiomyocyte-like cells and competitively bound CVB3 to immobilize the virus and prevent further infection of host cells. GCs acted as virus decoys to inhibit in vivo CVB3 infectivity, and the technology of intracellular gelation on the host cell provided a new insight into neutralizing the corresponding virus without screening the specific neutralizing antibody.

PEG-DA and Irgacure 2959 (I2959) are commonly used for photochemical cross-linking of hydrogels.27 This study transferred the cross-linking process into the intracellular cytoplasm. To maximize intracellular infiltration and minimize interference to cardiomyocytes, we employed PEG-DA with a low molecular weight (600 Da) and I2959 at a low concentration (10%, wt %). Successful cross-linking of PEG-DA and I2959 was achieved after UV (365–370 nm) irradiation at 6 W for 15 min, while a mixture without UV irradiation failed to form a hydrogel (Figure S1). Cardiomyocytes were chosen as host cells to construct GCs via intracellular gelation due to their highly selective recognition and susceptibility to CVB3 infection. Previous reports have indicated that frozen dead cells also serve as drug carriers for targeted delivery due to the interaction between the membrane receptor and cytokines or chemokines at the lesion site.28 Therefore, alongside the construction of GCs, dead cells were obtained via a freezing–thaw cycle and used as nongelated dead cells (NGDs) for comparison. HL-1 in the logarithmic growth phase was treated with PEG-DA and I2959 after a freezing–thaw cycle to enhance the intracellular infiltration. Subsequently, these cells were placed on ice and exposed to ultraviolet light (UV) to construct GCs. The low-temperature condition was implemented to prevent protein degradation and the denaturation of GCs. After 24 h of storage in PBS solution at room temperature, GCs retained an intact cellular morphology (Figure 2A), similar to that of live cells. This outcome indicated that the intracellular hydrogel effectively maintained a stable cellular structure and cytoskeleton. HL-1 cells treated with PEG-DA and I2959 without UV irradiation failed to form GCs. Moreover, NGDs could not retain an intact morphology and rapidly degraded into cell fragments at room temperature. Scanning electron microscopy (SEM) results further corroborated the similarity in morphology between GCs and live cells, while transmission electron microscopy (TEM) displayed the successful intracellular gelation of GCs (Figure 2B and 2C). DiD membrane staining revealed that GCs possessed an intact fluorescent membrane structure, whereas NGDs exhibited scattered and agglomerated cell membrane fragments and missed nuclei (Figure S2A). Cell diameter measurements indicated that the size of the GCs was consistent with that of live cells (Figure S2B). Flow cytometry results demonstrated a similar plot distribution between GCs and live cells, while NGDs appeared fragmented (Figure S2C). To ensure the stability of GCs under different conditions, GCs were stored at room temperature and subjected to repeated freezing and thawing at −80 °C for 15 days, respectively. The results indicated that GCs maintained their cellular structure regardless of storage at room temperature or under frozen conditions (Figure 2D,E). Collectively, these results suggested that GCs possess intact cell morphology, good structural stability, and storage properties in vitro.

Figure 2.

Figure 2

Engineering and characterization of GCs. (A) Representative microscopic images of the Live group, NGD group, PEG-DA group, I2959 group, and GC group. Each group of cells, except for the Live group, was incubated in PBS for 24 h. (B) Scanning electron microscopy (SEM) images of Live cells, NGDs, and GCs. (C) Transmission electron microscopy (TEM) images of Live cells, NGDs, and GCs. (D, E) Stability of GCs in 1 × PBS over a span of 15 days at room temperature (D) and through repeated freezing–thaw cycles (E), determined by flow cytometry. NS = nonsignificant, **P ≤ 0.01 and ***P ≤ 0.001.

To investigate protein loss in intracellular gelation, the protein profile of GCs was analyzed using SDS-PAGE. The results revealed that the protein band of GCs was almost consistent with that of live cells (Figure 3A), corroborated by BCA results (Figure S3A). Cardiomyocyte skeletal protein α-actin was examined using immunofluorescence, displaying consistency with live cells and undamaged protein structural domains (Figure 3B). The CCK8 assay results showed that GCs had no proliferative ability (Figure 3C). Annexin–V-PI staining revealed that GCs were dead cells, while all cells in the NGD group died, with a normal cell mortality rate of about 8.75% after 1 day (Figures 3D and S3B). HL-1 cell viability with different GC proportions (1:10, 1:1, and 10:1) revealed good biocompatibility (Figure 3E). HeLa and HL-1 cells were incubated with 100 TCID50 CVB3 and 1 × 106 GCs for 2 h to check whether GCs could neutralize CVB3 and protect those host cells. After 24 h, GCs in the supernatant were removed, and the mRNA level of CVB3 in cells was detected by a real-time fluorescence quantitative polymerase chain reaction (RT-PCR). The results indicated that HeLa and HL-1 cells were easily infected with CVB3, while GCs significantly reduced the expression of CVB3 mRNA in both cell types, indicating that GCs inhibited CVB3 infection (Figures 3F and S3C). Additionally, the cell fragments in the NGD group also exhibited a similar inhibition effect against CVB3 infection. Viral plaque results showed reduced viral plaques in both NGD and GC groups compared to the PC group, due to GCs binding and neutralizing CVB3, inhibiting its infection (Figure 3G). Additional antiviral experiments with GCs diluted at 1/2 concentration showed that 1 × 106 GCs coincubated with HeLa cells completely inhibited CVB3 infection, in a concentration-dependent manner (Figure S3D). To rule out the possibility of physical barrier effects by GCs, we preincubated GCs with the virus for 30 min, collected the supernatant, and infected HeLa cells. GCs still effectively inhibited the CVB3 virus infection (Figure S3E). Overall, the results suggest that GCs maintain the host cell cytoskeleton and efficiently preserve membrane proteins, neutralizing the CVB3 virus and suppressing infection. The replication and infection processes of CVB3 are complex, including interaction between virus particles and host receptors, fusion of a virion envelope and cell membrane, nucleocapsid decapitation, and release of the RNA genome into the cytoplasm. Obviously, the in vitro anti-infection effect of GCs was mainly through binding and neutralizing the virus and then immobilizing it to inhibit further interaction between virus particles and receptors of the host cell. Of note, the virus could be not replicated after being attached on the GC surface due to the noncell viability.

Figure 3.

Figure 3

GCs inhibit CVB3 infection in normal host cells. (A) Coomassie blue analysis using SDS-PAGE in Live cells, NGDs, and GCs. (B) Immunofluorescent staining for α-actin. (C) Proliferation curves of HL-1 cells and GCs assessed by a CCK8 assay at 24 h. (D) Cell death detected by Annexin V/PI double staining and flow cytometry. (E) Effect of different doses of GCs (number ratio between GC and HL-1 cell, 1:10, 1:1, and 10:1) on HL-1 cell proliferation assessed by the CCK8 assay at 0, 24, and 48 h. (F) RT-PCR detection of CVB3 RNA levels in HeLa cells with or without the addition of NGDs and GCs. NC: Negative control. PC: Positive control with CVB3. (G) Plaque morphology of CVB3 on HeLa cells with or without the addition of NGDs and GCs. PFU: Plaque-forming units. NS = not significant, **P ≤ 0.01 and ***P ≤ 0.001.

The potential systemic biosafety of GCs is a significant concern for clinical translation, as an intracellular hydrogel may induce physiological toxicity and immunogenicity. To evaluate acute toxicity, Balb/c mice received intravenous injections of 1 × 106 GCs every other day for 5 doses, with no apparent side effects or weight differences observed in both normal and GC-treated mice (Figure 4A). Comprehensive blood tests and serum analyses confirmed consistent levels of virus-infection-related biomarkers (ALT and AST) between GC-treated and control groups (Figure 4B). Lymphocyte (LYM) proportions decreased, while monocyte (MON) and granulocyte (GRA) proportions increased during CVB3 infection.29 Our examination of lymphocytes, monocytes, and granulocytes (Figure 4C) and other blood biomarkers (Figure 4D) showed no significant differences between GCs and control groups. These results confirm the short-term safety of GCs. Histopathological analysis of collected organs (heart, liver, spleen, lung, and kidney) showed no immune infiltration, lesion formation, or tissue injury in GC-treated mice (Figure 4E), indicating good in vivo biocompatibility. To track the in vivo biological distribution, we stained HL-1 cells with DiD before intracellular gelation and prepared them into nanoparticle cells (NS) and GCs. Live imaging revealed that the GC group exhibited the strongest fluorescence signal at 24 h, gradually decreasing after 48 h. In contrast, the fluorescence intensity of the NS group, prepared with the same cell quantity, was significantly lower than that of the GC group (Figure 4F). GCs first entered the lungs at 6 h and then moved to the liver and spleen for metabolism. By 72 h, GCs’ fluorescence intensity noticeably reduced. Conversely, the NS group’s fluorescence intensity rapidly declined after 24 h (Figure S4A). These results suggest that GCs have a long circulation time, sufficient to achieve adequate virus neutralization, and may transport captured viruses to organs, such as the lungs, liver, and spleen for metabolism and elimination. Although our small-scale preliminary safety study met the requirements for acute in vivo toxicity in VMC mice over 7 days, further exploration is still needed to investigate the long-term toxicity of GCs on a larger scale.

Figure 4.

Figure 4

In vivo safety assessment of GCs. (A) Balb/c mice were intravenously injected with 1 × 106 GCs every 2 days with a total of four doses (n = 5), and the body weight was recorded at experimental end points (day 7). (B) Comprehensive serum chemistry analysis was performed at day 7. Measurement parameters included TB (total bilirubin), ALB (albumin), AST (aspartate aminotransferase), ALT (alanine aminotransferase), CREA (creatinine), UREA (blood urea nitrogen), GLU (glucose), TBIL (total bilirubin), ALP (alkaline phosphatase), and IgG (immunoglobulin G). (C) Lymphocyte (LYM), monocyte (MON), and granulocyte (GRA) counts were detected at day 7. (D) Complete blood count collected from GC group mice was analyzed at day 7. The detected items included HGB (hemoglobin), RBC (red blood cells), HCT (hematocrit), MCV (mean corpuscular volume), MCH (mean corpuscular hemoglobin), MCHC (mean corpuscular hemoglobin concentration), RDW (red cell distribution width), PLT (platelets), PCT (platelet crit), MPV (mean platelet volume), PDW (platelet distribution width), and PLCR (platelet crit-to-large cell ratio). (E) Histopathological analysis of the heart, liver, spleen, lung, and kidney using H&E-stained tissue sections. Scale bar: 100 μm. (F) Mice were intravenously (i.v.) injected with NS and GCs at a number of 1 × 106 cells per mouse, and the fluorescence signals were detected using an in vivo imaging system (D-22 cm) after administration at 6, 12, 24, 48, 72, 96, and 120 h (n = 7). NS = nonsignificant, **P ≤ 0.01 and ***P ≤ 0.001.

As a novel cellular decoy, we investigated the antiviral efficacy of GCs in CVB3-infected mice. CVB3-induced viral myocarditis peaks at day 7 and gradually decreases.30 To construct the viral myocarditis model, we intraperitoneally injected mice with 1 × 105 TCID50 CVB3. We first conducted a comparative analysis of the in vivo biosafety of NGDs and GCs. The results indicated that all mice in the NGD group succumbed 1 day postadministration (Figure 5A), possibly due to the cell fragments inducing a pulmonary embolism.31,32 In contrast, the GC group showed no fatalities, indicating higher biosafety. Therefore, despite that NGDs exhibit effective viral neutralization capabilities in vitro, their biosafety is considerably low. Subsequently, we tested the in vivo antiviral capabilities of GCs. Mice were divided into five groups: the NC, CVB3, NS, GCs, and Ribavirin groups. Each group of mice received an injection every other day, for a total of 7 injections. On day 2 after CVB3 inoculation, mice in the CVB3 group experienced rapid body weight decline, whereas the NS, GC, and Ribavirin groups exhibited improved body weight trends (Figure 5B). On day 7, we evaluated the CVB3 viral load and IFN-β, IFN-γ, and Fas expression levels related to myocardial cell damage and serum indicators closely related to viral infection (cTnI, CK, CK-MB, LDH, and LDH-L). The CVB3 group showed significantly increased myocardial injury-related indicators. In contrast, the NS, GC, and Ribavirin groups exhibited reduced viral titers and alleviated myocardial cell damage. Specifically, the antiviral effect of the GC group was close to that of the Ribavirin group. Additionally, the GC group showed significantly reduced AST and ALT levels and an increased proportion of monocytes and neutrophils in the peripheral blood (Figure S5A and S5B), effectively alleviating viral myocarditis. No significant changes were observed in other blood parameters (Figures S5C and S5D). Notably, although NS inhibited CVB3-induced viral myocarditis, the dosage difference between GCs and NS means that GCs could significantly enhance the neutralizing efficiency against the virus. Finally, we collected the heart, liver, spleen, lungs, and kidneys of mice on days 3, 7, and 14 for pathological analysis. The GC group effectively improved CVB3-induced viral myocarditis, with an inhibitory effect comparable to the Ribavirin group (Figure 5L). H&E staining of the liver, spleen, lungs, and kidneys in all groups was similar to that of normal mice, with no evidence of pathological changes or tissue damage (Figure S6).

Figure 5.

Figure 5

In vivo therapy of GCs against CVB3 infection. (A) Survival rates of CVB3-infected mice after iv injection with NGDs and GCs (n = 5). (B) CVB3-infected mice were iv administered with 100 μL of PBS (100 μL per mouse), NS (prepared from 1 × 107 cardiomyocytes), GCs (1 × 106), and Ribavirin (50 mg/kg), every other day for a total of 7 injections, and body weight change curves of mice were created (n = 7). (C) RT-PCR detection of CVB3 RNA levels in the heart. (D–F) RT-PCR detection of IFN-β, IFN-γ, and Fas mRNA levels in the heart. (G) ELISA detects serum cTnI levels. (H–K) Serum CK, CK-MB, LDH, and LDH-L analyses were performed on day 7. (L) Histopathological analysis of the heart, liver, spleen, lung, and kidney using H&E-stained tissue sections on day 3, day 7, and day 14. *P ≤ 0.05, **P ≤ 0.01, and ***P ≤ 0.001.

Biological neutralization represents an emerging antiviral infection strategy developed in recent years. Up to now, the technology of utilizing cell-membrane-coated nanoparticles has been applied to the neutralization of various viruses,33 such as HIV,25 the Zika virus,24 and SARS-CoV-2.34 In addition, biological neutralization including a neutralizing antibody demonstrated therapeutic effectiveness, through binding to a cell-free virus and preventing it from infecting cells.35,36 However, the main challenge relies on the slow development rate of neutralizing antibodies, and the time-consuming process leads to an inadequately rapid response to virus spread. The envelope or capsid proteins of the virus primarily recognized the specific receptors on the host cell membrane, facilitating virus attachment, endocytosis, and replication.37 Based on the virus infection characterization of the receptor–ligand interaction,38 a host membrane camouflaged strategy was developed as a decoy to competitively absorb the virus and prevent further virus infection. For example, the CD4+ T cell membrane was collected to encapsulate PLGA nanoparticles, and membranes CXCR4 and CCR5 specifically bound HIV gp120 to neutralize HIV and inhibit CD4+ T cell apoptosis.25 The Zika virus is a mosquito-borne virus causing neurological disorders and congenital disabilities such as microcephaly, and the biomimetic mosquito C6/36 cell membrane coated gelatin nanoparticles neutralized the Zika virus, reducing fetal microcephaly by preventing the virus from crossing the placental blood barrier.24 CD147 has been identified as a receptor for SARS-CoV-2. Biomimetic nanoparticles derived from the membrane of SARS-CoV-2-susceptible human pulmonary epithelial type II cells or human macrophages show a dose-dependent inhibitory effect on the infectivity of SARS-CoV-2.34 In summary, cell membrane biomimetic nanomedicine has been proven to be a unique and effective approach for neutralizing viruses.

However, the construction process of membrane-coated nanomedicine involves cell disruption and membrane separation and subsequent membrane coating and reassembly on template nanoparticles, which can induce membrane protein loss and spatial disorder. As a result, the domain responsible for virus binding may be hindered or disrupted, reducing the adsorption capacity of the biomimetic nanomedicines. In addition, incomplete membrane-coated nanomedicine enhanced the risk of systemic clearance by monocyte phagocytosis as “foreign substances”. Therefore, it is crucial to ensure that the cell membrane structure and physiological characteristics are not damaged during the preparation of a biomimetic nanomedicine. To overcome these limitations, we prepared a biocompatible hydrogel as an ideal cytoskeleton to stabilize the morphology and membrane protein of virus-susceptible cells and enhance their absorption efficiency for antiviral neutralization. In vivo safety evaluation and biodistribution demonstrated that GCs had excellent biocompatibility, immune evasion capability, and prolonged retention time in the infected tissue. HL-1 cells derived from mouse hearts possessed a strong affinity to bind CVB3, and intracellular gelation technology was employed to construct a cell sponge to capture and neutralize systemic and localized CVB3 and prevent further infection on cardiomyocytes. In our future research, we aim to engineer antibody receptors by gene manipulation. Specifically, we plan to express the Fab fragments of highly effective virus-neutralizing antibodies on the surface of GCs through genetic engineering, thereby enabling the adsorption and disintegration of viruses. This will further improve the adsorption capacity of GCs and facilitate virus capture and neutralization.

This study emphasizes the use of cardiomyocytes in preclinical exploratory research. It is noteworthy that during the clinical translation phase autologous or allogeneic cardiac myocytes may face complex challenges such as difficulties in harvesting and immune rejection. As a result, alternative cells may become a highly prospective solution. Our research’s core concept focuses on utilizing the high specificity of host cells to adsorb and neutralize viruses, providing potential alternatives for other cells with similar high-affinity characteristics. Overall, the primary contribution of this study is the introduction of an innovative antiviral strategy based on intracellular gelation. This strategy, rooted in the unique features of intracellular gel technology, can effectively overcome the “high-pressure selection” mutation challenges that traditional antiviral methods find difficult to address. Even if the virus mutates, its recognition pattern may remain relatively stable, thereby reducing the risk of the virus escaping neutralization. Facing the outbreak of an epidemic, especially when viruses spread and mutate rapidly, the development cycle of traditional drugs and vaccines may be prolonged, making them less suitable for a rapid response. However, the intracellular gelation strategy proposed in this study, due to its rapid applicability, can be deployed and promoted in a short time, making it a swift antiviral response solution. By employing intracellular gelation in host cells, we have not only demonstrated an innovative and promising antiviral technology but also, more importantly, provided a universal and practically feasible solution for handling urgent epidemic outbreaks, such as those similar to COVID-19.

Acknowledgments

This work was supported by National Key Research and Development Program of China (2022YFC2302700), National Natural Science Foundation of China (32001016, 32371381), Guangdong Basic and Applied Basic Research Foundation (2020A1515110871, 2022A1515220006), Guangdong Science and Technology Foundation (2021A1515220084, 2022B1111020001), China Postdoctoral Science Foundation (2022M722204), and Shenzhen Science and Technology Foundation (GJHZ20200731095604013, JSGG20220301090003004, 201906133000069, SGLH20180625171602058, JCYJ20200109120205924, RCBS20200714114856016, JCYJ20210324103204011).

Supporting Information Available

The Supporting Information is available free of charge at https://pubs.acs.org/doi/10.1021/acs.nanolett.3c01983.

  • Experimental materials and methods as well as supplementary figures, including characterization of hydrogels, SEM images of GCs, cell death in a live cell group, CVB3 RNA levels in HL-1 cells with or without the addition of NGDs and GCs, plaque morphology of CVB3 in HeLa cells with or without GCs, in vivo metabolism and distribution of GCs, serological analysis, and results of H&E pathological analysis (PDF)

Author Contributions

J.W., T.L., and S.G. contributed equally to this work. Methodology: D.G., C.G., W.X. and J.W.; Experiment: J.W., T.L. and S.G.; Writing-original draft: J.W.; Writing-review and editing: T.L. and S.G.; Data curation: J.W., T.L., S.G. and H.Y.; Supervision: D.G., C.G. and W.X.; Funding acquisition: D.G., C.G. and J.W.

Author Contributions

# J.W., T.L., and S.G. contributed equally to this work. Methodology: D.G., C.G., W.X., and J.W. Experiment: J.W., T.L., and S.G. Writing-original draft: J.W. Writing-review and editing: T.L. and S.G. Data curation: J.W., T.L., S.G., and H.Y. Supervision: D.G., C.G., and W.X. Funding acquisition: D.G., C.G., and J.W.

The authors declare no competing financial interest.

Supplementary Material

nl3c01983_si_001.pdf (1.3MB, pdf)

References

  1. Stone V. M.; Hankaniemi M. M.; Laitinen O. H.; Sioofy-Khojine A. B.; Lin A.; Diaz Lozano I. M.; Mazur M. A.; Marjomaki V.; Lore K.; Hyoty H.; et al. A hexavalent Coxsackievirus B vaccine is highly immunogenic and has a strong protective capacity in mice and nonhuman primates. Sci. Adv. 2020, 6 (19), eaaz2433 10.1126/sciadv.aaz2433. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Shih W. L.; Tung Y. C.; Chang L. Y.; Fang C. T.; Tsai W. Y. Increased Incidence of Pediatric Type 1 Diabetes With Novel Association With Coxsackievirus A Species in Young Children but Declined Incidence in Adolescents in Taiwan. Diabetes Care 2021, 44 (7), 1579–1585. 10.2337/dc20-1092. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Kallewaard N. L.; Zhang L.; Chen J. W.; Guttenberg M.; Sanchez M. D.; Bergelson J. M. Tissue-specific deletion of the coxsackievirus and adenovirus receptor protects mice from virus-induced pancreatitis and myocarditis. Cell Host Microbe 2009, 6 (1), 91–98. 10.1016/j.chom.2009.05.018. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Mohamud Y.; Tang H.; Xue Y. C.; Liu H.; Ng C. S.; Bahreyni A.; Luo H. Coxsackievirus B3 targets TFEB to disrupt lysosomal function. Autophagy 2021, 17 (12), 3924–3938. 10.1080/15548627.2021.1896925. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Weithauser A.; Bobbert P.; Antoniak S.; Bohm A.; Rauch B. H.; Klingel K.; Savvatis K.; Kroemer H. K.; Tschope C.; Stroux A.; et al. Protease-activated receptor-2 regulates the innate immune response to viral infection in a coxsackievirus B3-induced myocarditis. J. Am. Coll Cardiol 2013, 62 (19), 1737–1745. 10.1016/j.jacc.2013.05.076. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Rivadeneyra L.; Charo N.; Kviatcovsky D.; de la Barrera S.; Gomez R. M.; Schattner M. Role of neutrophils in CVB3 infection and viral myocarditis. J. Mol. Cell Cardiol 2018, 125, 149–161. 10.1016/j.yjmcc.2018.08.029. [DOI] [PubMed] [Google Scholar]
  7. Liu X.; Wang X.; Kapteijn F. Water and Metal-Organic Frameworks: From Interaction toward Utilization. Chem. Rev. 2020, 120 (16), 8303–8377. 10.1021/acs.chemrev.9b00746. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Sainz B. Jr.; Barretto N.; Martin D. N.; Hiraga N.; Imamura M.; Hussain S.; Marsh K. A.; Yu X.; Chayama K.; Alrefai W. A.; et al. Identification of the Niemann-Pick C1-like 1 cholesterol absorption receptor as a new hepatitis C virus entry factor. Nat. Med. 2012, 18 (2), 281–285. 10.1038/nm.2581. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Voros J.; Urbanek A.; Rautureau G. J.; O’Connor M.; Fisher H. C.; Ashcroft A. E.; Ferguson N. Large-scale production and structural and biophysical characterizations of the human hepatitis B virus polymerase. J. Virol 2014, 88 (5), 2584–2599. 10.1128/JVI.02575-13. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Schmidt F.; Weisblum Y.; Muecksch F.; Hoffmann H. H.; Michailidis E.; Lorenzi J. C. C.; Mendoza P.; Rutkowska M.; Bednarski E.; Gaebler C.; et al. Measuring SARS-CoV-2 neutralizing antibody activity using pseudotyped and chimeric viruses. J. Exp Med. 2020, 217 (11), e20201181 10.1084/jem.20201181. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Chi X.; Liu X.; Wang C.; Zhang X.; Li X.; Hou J.; Ren L.; Jin Q.; Wang J.; Yang W. Humanized single domain antibodies neutralize SARS-CoV-2 by targeting the spike receptor binding domain. Nat. Commun. 2020, 11 (1), 4528. 10.1038/s41467-020-18387-8. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Li C.; Yu D.; Wu X.; Liang H.; Zhou Z.; Xie Y.; Li T.; Wu J.; Lu F.; Feng L.; et al. Twelve-month specific IgG response to SARS-CoV-2 receptor-binding domain among COVID-19 convalescent plasma donors in Wuhan. Nat. Commun. 2021, 12 (1), 4144. 10.1038/s41467-021-24230-5. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Bauer G.; Struck F.; Staschik E.; Maile J.; Wochinz-Richter K.; Motz M.; Soutschek E. Differential avidity determination of IgG directed towards the receptor-binding domain (RBD) of SARS-CoV-2 wild-type and its variants in one assay: Rational tool for the assessment of protective immunity. J. Med. Virol 2022, 94 (11), 5294–5303. 10.1002/jmv.28006. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Hanke L.; Das H.; Sheward D. J.; Perez Vidakovics L.; Urgard E.; Moliner-Morro A.; Kim C.; Karl V.; Pankow A.; Smith N. L.; et al. A bispecific monomeric nanobody induces spike trimer dimers and neutralizes SARS-CoV-2 in vivo. Nat. Commun. 2022, 13 (1), 155. 10.1038/s41467-021-27610-z. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Guo X.; Wen F.; Zheng N.; Saive M.; Fauconnier M. L.; Wang J. Aptamer-Based Biosensor for Detection of Mycotoxins. Front Chem. 2020, 8, 195. 10.3389/fchem.2020.00195. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Mahajan S. P.; Ruffolo J. A.; Frick R.; Gray J. J. Hallucinating structure-conditioned antibody libraries for target-specific binders. Front Immunol 2022, 13, 999034. 10.3389/fimmu.2022.999034. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Stergioti E. M.; Manolakou T.; Boumpas D. T.; Banos A. Antiviral Innate Immune Responses in Autoimmunity: Receptors, Pathways, and Therapeutic Targeting. Biomedicines 2022, 10 (11), 2820. 10.3390/biomedicines10112820. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Chang H.; Li X.; Cai Q.; Li C.; Tian L.; Chen J.; Xing X.; Gan Y.; Ouyang W.; Yang Z. The PI3K/Akt/mTOR pathway is involved in CVB3-induced autophagy of HeLa cells. Int. J. Mol. Med. 2017, 40 (1), 182–192. 10.3892/ijmm.2017.3008. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Xu L.; Zheng Q.; Zhu R.; Yin Z.; Yu H.; Lin Y.; Wu Y.; He M.; Huang Y.; Jiang Y.; et al. Cryo-EM structures reveal the molecular basis of receptor-initiated coxsackievirus uncoating. Cell Host Microbe 2021, 29 (3), 448–462. 10.1016/j.chom.2021.01.001. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Kicmal T. M.; Tate P. M.; Dial C. N.; Esin J. J.; Mounce B. C. Polyamine Depletion Abrogates Enterovirus Cellular Attachment. J. Virol 2019, 93 (20), 01054-01019 10.1128/JVI.01054-19. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Plevka P.; Perera R.; Cardosa J.; Kuhn R. J.; Rossmann M. G. Crystal structure of human enterovirus 71. Science 2012, 336 (6086), 1274. 10.1126/science.1218713. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Gao C.; Huang Q.; Liu C.; Kwong C. H. T.; Yue L.; Wan J. B.; Lee S. M. Y.; Wang R. Treatment of atherosclerosis by macrophage-biomimetic nanoparticles via targeted pharmacotherapy and sequestration of proinflammatory cytokines. Nat. Commun. 2020, 11 (1), 2622. 10.1038/s41467-020-16439-7. [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. Chen Y.; Chen M.; Zhang Y.; Lee J. H.; Escajadillo T.; Gong H.; Fang R. H.; Gao W.; Nizet V.; Zhang L. Broad-Spectrum Neutralization of Pore-Forming Toxins with Human Erythrocyte Membrane-Coated Nanosponges. Adv. Healthc Mater. 2018, 7 (13), 1701366 10.1002/adhm.201701366. [DOI] [PMC free article] [PubMed] [Google Scholar]
  24. Rao L.; Wang W.; Meng Q. F.; Tian M.; Cai B.; Wang Y.; Li A.; Zan M.; Xiao F.; Bu L. L.; et al. A Biomimetic Nanodecoy Traps Zika Virus To Prevent Viral Infection and Fetal Microcephaly Development. Nano Lett. 2019, 19 (4), 2215–2222. 10.1021/acs.nanolett.8b03913. [DOI] [PubMed] [Google Scholar]
  25. Wei X.; Zhang G.; Ran D.; Krishnan N.; Fang R. H.; Gao W.; Spector S. A.; Zhang L. T-Cell-Mimicking Nanoparticles Can. Neutralize HIV Infectivity. Adv. Mater. 2018, 30 (45), 1802233 10.1002/adma.201802233. [DOI] [PMC free article] [PubMed] [Google Scholar]
  26. Heymans S.; Eriksson U.; Lehtonen J.; Cooper L. T. Jr. The Quest for New Approaches in Myocarditis and Inflammatory Cardiomyopathy. J. Am. Coll Cardiol 2016, 68 (21), 2348–2364. 10.1016/j.jacc.2016.09.937. [DOI] [PubMed] [Google Scholar]
  27. Rennerfeldt D. A.; Renth A. N.; Talata Z.; Gehrke S. H.; Detamore M. S. Tuning mechanical performance of poly(ethylene glycol) and agarose interpenetrating network hydrogels for cartilage tissue engineering. Biomaterials 2013, 34 (33), 8241–8257. 10.1016/j.biomaterials.2013.07.052. [DOI] [PMC free article] [PubMed] [Google Scholar]
  28. Ci T.; Li H.; Chen G.; Wang Z.; Wang J.; Abdou P.; Tu Y.; Dotti G.; Gu Z. Cryo-shocked cancer cells for targeted drug delivery and vaccination. Sci. Adv. 2020, 6 (50), eabc3013 10.1126/sciadv.abc3013. [DOI] [PMC free article] [PubMed] [Google Scholar]
  29. Hu Y.; Ren J.; Dong X.; Zhang D.; Qu Y.; Yang C.; Sun Y.; Li J.; Luo F.; Wang W.; et al. Fulminant Giant Cell Myocarditis vs. Lymphocytic Myocarditis: A Comparison of Their Clinical Characteristics, Treatments, and Outcomes. Front Cardiovasc Med. 2021, 8, 770549. 10.3389/fcvm.2021.770549. [DOI] [PMC free article] [PubMed] [Google Scholar]
  30. Tian Y.; Gong X.; Qin D.; Cao Y.; Zhang S.; Xia L.; Liu F.; Su Z. S1PR1-dependent migration of ILC3s from intestinal tissue to the heart in a mouse model of viral myocarditis. J. Leukoc Biol. 2023, 114 (2), 154–163. 10.1093/jleuko/qiad048. [DOI] [PubMed] [Google Scholar]
  31. Lee H. S.; Kang N. W.; Kim H.; Kim D. H.; Chae J. W.; Lee W.; Song G. Y.; Cho C. W.; Kim D. D.; Lee J. Y. Chondroitin sulfate-hybridized zein nanoparticles for tumor-targeted delivery of docetaxel. Carbohydr. Polym. 2021, 253, 117187. 10.1016/j.carbpol.2020.117187. [DOI] [PubMed] [Google Scholar]
  32. Xu Y.; Yang Y.; Zheng H.; Huang C.; Zhu X.; Zhu Y.; Guan R.; Xin Z.; Liu Z.; Tian Y. Intracavernous injection of size-specific stem cell spheroids for neurogenic erectile dysfunction: Efficacy and risk versus single cells. EBioMedicine 2020, 52, 102656. 10.1016/j.ebiom.2020.102656. [DOI] [PMC free article] [PubMed] [Google Scholar]
  33. Xiao M.; Tian F.; Liu X.; Zhou Q.; Pan J.; Luo Z.; Yang M.; Yi C. Virus Detection: From State-of-the-Art Laboratories to Smartphone-Based Point-of-Care Testing. Adv. Sci. (Weinh) 2022, 9 (17), e2105904 10.1002/advs.202105904. [DOI] [PMC free article] [PubMed] [Google Scholar]
  34. Zhang Q.; Honko A.; Zhou J.; Gong H.; Downs S. N.; Vasquez J. H.; Fang R. H.; Gao W.; Griffiths A.; Zhang L. Cellular Nanosponges Inhibit SARS-CoV-2 Infectivity. Nano Lett. 2020, 20 (7), 5570–5574. 10.1021/acs.nanolett.0c02278. [DOI] [PubMed] [Google Scholar]
  35. Wang S.; Wang D.; Duan Y.; Zhou Z.; Gao W.; Zhang L. Cellular Nanosponges for Biological Neutralization. Adv. Mater. 2022, 34 (13), e2107719 10.1002/adma.202107719. [DOI] [PubMed] [Google Scholar]
  36. Lanza R.; Russell D. W.; Nagy A. Engineering universal cells that evade immune detection. Nat. Rev. Immunol 2019, 19 (12), 723–733. 10.1038/s41577-019-0200-1. [DOI] [PubMed] [Google Scholar]
  37. Fredericksen B. L.; Wei B. L.; Yao J.; Luo T.; Garcia J. V. Inhibition of endosomal/lysosomal degradation increases the infectivity of human immunodeficiency virus. J. Virol 2002, 76 (22), 11440–11446. 10.1128/JVI.76.22.11440-11446.2002. [DOI] [PMC free article] [PubMed] [Google Scholar]
  38. Gao W.; Zhang Y.; Zhang Q.; Zhang L. Nanoparticle-Hydrogel: A Hybrid Biomaterial System for Localized Drug Delivery. Ann. Biomed Eng. 2016, 44 (6), 2049–2061. 10.1007/s10439-016-1583-9. [DOI] [PMC free article] [PubMed] [Google Scholar]

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Supplementary Materials

nl3c01983_si_001.pdf (1.3MB, pdf)

Articles from Nano Letters are provided here courtesy of American Chemical Society

RESOURCES